Ingersoll Rand Schedules First Quarter 2025 Earnings Release and Conference Call
Get Alerts IR Hot Sheet
Join SI Premium – FREE
DAVIDSON, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Ingersoll Rand Inc. (NYSE: IR), a global provider of mission-critical flow creation and life science and industrial solutions, will issue its first quarter 2025 earnings release after the market closes on Thursday, May 1, 2025.
Ingersoll Rand will also host a live earnings conference call to discuss the first quarter results on Friday, May 2, 2025, at 8 a.m. Eastern Time. To participate in the call, please dial +1-888-330-3073, domestically, or +1-646-960-0683, internationally, and use access code 8970061.
A real-time audio webcast of the presentation can be accessed via the Events and Presentations section of the Ingersoll Rand Investor Relations website here, where related materials will be posted prior to the conference call.
A replay of the webcast will be available after conclusion of the conference and can be accessed on Investor Relations Website here.
About Ingersoll Rand Inc.
Ingersoll Rand Inc. (NYSE: IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to Making Life Better for our employees, customers, shareholders, and planet. Customers lean on us for exceptional performance and durability in mission-critical flow creation and life science and industrial solutions. Supported by over 80+ respected brands, our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity, and efficiency. For more information, visit www.IRCO.com.
Investors:
Matthew Fort
[email protected]
Media:
Sara Hassell
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Is Treasury selloff a major issue for stock market bulls?
- InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share